Interim Report (Half Year) H2 2018: Resverlogix reports deterioration in EPS Corporate Wire Date: 31 December 2018 22:58 EST
Resverlogix (TSX:RVX) announced EPS of -49.0c for the half year-ended 31 October 2018, a deterioration from -24.0c in the previous corresponding period.
Major changes compared with previous corresponding period [Year-on-Year]:
- EPS deterioration 104.2% from -24.0c to -49.0c
- Loss of $US88.7m
Interim (Half Year)
ACTIVITIES: Resverlogix Corp is a clinical stage cardiovascular company developing compounds involving ...